Ciclesonide (Systemic, Oral Inhalation)
Brand names: Alvesco
Drug class:
Antineoplastic Agents
Usage of Ciclesonide (Systemic, Oral Inhalation)
Asthma
Long-term prevention of bronchospasm in patients with asthma.
In corticosteroid-dependent patients, may permit a reduction in dosage or discontinuance of systemic corticosteroids.
Not indicated for management of acute bronchospasm.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Ciclesonide (Systemic, Oral Inhalation)
General
Conversion to Orally Inhaled Therapy in Patients Receiving Systemic Corticosteroids
Administration
Oral Inhalation
Administer by oral inhalation using an oral aerosol inhaler.
Test-spray aerosol (3 times) before first use or when the inhaler is unused for >10 days.
Oral inhalation aerosol is formulated as a solution, which does not require shaking.
Exhale completely and place the mouthpiece of the inhaler well into the mouth with the lips closed firmly around it; keep the tongue below the mouthpiece. Inhale slowly and deeply through the mouth while pressing the canister down with forefinger. Hold the breath for about 10 seconds, or as long as comfortable, then withdraw the mouthpiece and exhale gently.
Patients receiving oral inhalation of ciclesonide should rinse their mouth with water after each dose to remove residual medication in the oropharyngeal area and to minimize the development of fungal overgrowth and/or infection.
Dosage
Pediatric Patients
Asthma Oral InhalationChildren ≥12 years of age receiving bronchodilators alone previously: Initially 80 mcg twice daily. If control of asthma is inadequate after 4 weeks of therapy at the initial dosage, a higher dosage may provide additional asthma control. If required, may increase dosage to a maximum of 160 mcg twice daily.
Children ≥12 years of age receiving inhaled corticosteroids previously: Initially 80 mcg twice daily. If control of asthma is inadequate after 4 weeks of therapy at the initial dosage, a higher dosage may provide additional asthma control. If required, may increase dosage to a maximum of 320 mcg twice daily.
Children ≥12 years of age receiving oral corticosteroids previously: 320 mcg twice daily.
Adults
Asthma Oral InhalationPreviously receiving bronchodilators alone: Initially 80 mcg twice daily. If control of asthma is inadequate after 4 weeks of therapy at the initial dosage, a higher dosage may provide additional asthma control. If required, may increase dosage to a maximum of 160 mcg twice daily.
Previously receiving inhaled corticosteroids: Initially 80 mcg twice daily. If control of asthma is inadequate after 4 weeks of therapy at the initial dosage, a higher dosage may provide additional asthma control. If required, may increase dosage to a maximum of 320 mcg twice daily.
Previously receiving oral corticosteroids: 320 mcg twice daily.
Prescribing Limits
Pediatric Patients
Asthma Oral InhalationChildren ≥12 years of age receiving bronchodilators alone previously: Maximum 160 mcg twice daily.
Children ≥12 years of age receiving inhaled corticosteroids previously: Maximum 320 mcg twice daily.
Children ≥12 years of age receiving oral corticosteroids previously: Maximum 320 mcg twice daily.
Adults
Asthma Oral InhalationPreviously receiving bronchodilators alone: Maximum 160 mcg twice daily.
Previously receiving inhaled corticosteroids: Maximum 320 mcg twice daily.
Previously receiving oral corticosteroids: Maximum 320 mcg twice daily.
Special Populations
Hepatic Impairment
Dosage adjustment not required. (See Hepatic Impairment under Cautions.)
Renal Impairment
No specific dosage recommendations at this time. (See Renal Impairment under Cautions.)
Geriatric Patients
Careful dosage selection, usually initiating therapy at the low end of the dosage range, recommended due to possible age-related decrease in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.
Warnings
Contraindications
Warnings/Precautions
Sensitivity Reactions
Hypersensitivity reactions, including angioedema with swelling of the lips, tongue, and pharynx, reported.
Infections
Localized candidal infections of the mouth and/or pharynx reported.
If infection occurs, initiate appropriate local or systemic antifungal treatment while still continuing with inhaled ciclesonide therapy. May require interruption of ciclesonide therapy in some patients.
Use with caution, if at all, in patients with clinical or asymptomatic Mycobacterium tuberculosis infections of the respiratory tract; untreated systemic fungal, bacterial, parasitic, or viral infections; or ocular herpes simplex.
Acute Exacerbations of Asthma
Treat acute asthma symptoms with a short-acting β2-agonist bronchodilator. If symptoms persist, promptly reevaluate asthma therapy and consider initiating systemic corticosteroids.
Immunosuppressed Patients
Increased susceptibility to infections in patients who are taking immunosuppressive drugs compared with healthy individuals. Certain infections (e.g., varicella [chickenpox], measles) can have a more serious or even fatal outcome in such patients.
Take particular care to avoid exposure in susceptible patients. If exposure to varicella or measles occurs in susceptible patients, consider administering varicella zoster immune globulin (VZIG) or pooled immune globulin (IG), respectively. Consider treatment with an antiviral agent if varicella develops.
Withdrawal of Systemic Corticosteroid Therapy
Possible life-threatening adrenal insufficiency in patients being switched from systemic corticosteroids to orally inhaled ciclesonide.
Withdraw systemic corticosteroid therapy gradually and monitor carefully for objective signs of adrenal insufficiency (e.g., fatigue, lassitude, weakness, nausea, vomiting, hypotension) during withdrawal of systemic therapy. Lung function (FEV1 or morning peak expiratory flow rate [PEFR]), adjunctive β2-adrenergic agonist use, and asthma symptoms also should be carefully monitored. In most patients, several months are required for total recovery of HPA function following withdrawal of systemic corticosteroid therapy. Patients who have been maintained on ≥20 mg of prednisone (or its equivalent) daily may be most susceptible to such adverse events, particularly during the later part of the transfer. (See Conversion to Orally Inhaled Therapy in Patients Receiving Systemic Corticosteroids under Dosage and Administration.)
Corticosteroid withdrawal symptoms (e.g., joint pain, muscular pain, lassitude, depression) may occur; carefully monitor during and for a number of months after withdrawal of systemic corticosteroids.
Acute adrenal insufficiency may occur during exposure to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss.
Possible unmasking of allergic conditions previously controlled by systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions).
Systemic Corticosteroid Effects
Administration of higher than recommended dosages of inhaled ciclesonide over prolonged periods may result in manifestations of hypercorticism and suppression of HPA function. If such changes occur, reduce the dosage of ciclesonide slowly, consistent with accepted procedures for reducing systemic corticosteroid dosage and management of asthma symptoms.
Take particular care in monitoring patients postoperatively or during periods of stress for evidence of inadequate adrenal response. Supplemental therapy with a systemic corticosteroid required during stress or severe asthma attacks.
Musculoskeletal Effects
Long-term use of orally inhaled corticosteroids may affect normal bone metabolism, resulting in a loss of bone mineral density (BMD).
Monitor patients with major risk factors for decreased BMD (e.g., family history of osteoporosis, prolonged immobilization, chronic use of drugs that can reduce bone mass [e.g., anticonvulsants, corticosteroids]) and treat with established standards of care.
Ocular Effects
Glaucoma, increased IOP, and cataracts reported rarely in patients receiving orally inhaled corticosteroids. Carefully monitor patients who have a change in vision and those with a history of increased IOP, glaucoma, and/or cataracts.
Respiratory Effects
Bronchospasm and wheezing may occur with oral inhalation therapy.
If bronchospasm occurs, treat immediately with a short-acting bronchodilator, and discontinue treatment with ciclesonide and institute alternate therapy.
Specific Populations
PregnancyCategory C.
LactationDistributed into milk in rats; not known whether distributed into human milk. Caution if used in nursing women.
Pediatric UseSafety and efficacy not established in children <12 years of age.
With prolonged use, may slow growth rate in children and adolescents. Monitor routinely (e.g., via stadiometry) the growth and development of pediatric patients receiving corticosteroid therapy. Weigh benefits of corticosteroid therapy versus possibility of growth suppression and the risks associated with alternative therapies. Use the lowest possible dosage that effectively controls asthma.
Geriatric UseInsufficient experience with oral inhalation in patients ≥65 years of age to determine whether geriatric patients respond differently than younger patients. (See Geriatric Patients under Dosage and Administration.)
Hepatic ImpairmentIncreased systemic exposure in patients with moderate to severe hepatic impairment; however, dosage adjustments not necessary.
Renal ImpairmentPharmacokinetics not evaluated but impact of renal impairment should be minimal.
Common Adverse Effects
Headache, nasopharyngitis, sinusitis, pharyngolaryngeal pain, upper respiratory infection, arthralgia, nasal congestion, extremity pain, back pain, hoarseness, oral candidiasis, influenza, pneumonia, musculoskeletal chest pain, urticaria, dizziness, gastroenteritis, facial edema, fatigue, conjunctivitis.
What other drugs will affect Ciclesonide (Systemic, Oral Inhalation)
Inhibitory potential of ciclesonide on CYP isoenzymes not evaluated; however des-ciclesonide (active metabolite) does not inhibit or induce the metabolism of other drugs metabolized by CYP isoenzymes in vitro.
Ciclesonide and des-ciclesonide do not induce CYP isoenzymes in vitro.
Drugs Affecting Hepatic Microsomal Enzymes
Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased plasma des-ciclesonide concentrations).
Protein-bound Drugs
Pharmacokinetic interaction unlikely.
Specific Drugs
Drug
Interaction
Comments
Albuterol
Pharmacokinetic interaction with des-ciclesonide not observed
Erythromycin
Pharmacokinetic interaction not observed
Formoterol
Pharmacokinetic interaction with des-ciclesonide not observed
Ketoconazole
Increased plasma des-ciclesonide concentrations; however, plasma ciclesonide concentrations unchanged
Use concomitantly with caution; no specific dosage recommendations at this time
Salicylic acid
Pharmacokinetic interactions unlikely
Plasma protein binding of des-ciclesonide not altered by salicylic acid in vitro
Warfarin
Pharmacokinetic interactions unlikely
Plasma protein binding of des-ciclesonide not altered by warfarin in vitro
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions